Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 571-575

  Birnbaum, Angela K ^a   Ahn, Jae Eun ^a,c   Brundage, Richard C ^a   Hardie, Nancy A ^a   Conway, Jeannine M ^a   Leppik, Ilo E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINCEP Epilepsy Care   (United States)

^c ICON Development Solutions   (United States)

Author keywords

Elderly; Epilepsy; NONMEM; Pharmacokinetics; Valproic acid

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

AGED; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; GERIATRICS; HUMAN; MALE; NURSING HOME; NURSING HOME PATIENT; PRIORITY JOURNAL; SEX DIFFERENCE; SYRUP; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DRUG MONITORING; EPILEPSY; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; LONG-TERM CARE; MALE; METABOLIC CLEARANCE RATE; MINNESOTA; MODELS, THEORETICAL; POPULATION GROUPS; VALPROIC ACID;

EID: 34848821661     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f3296     Document Type: Article

References (22)

1. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med. 1994;3:589-598.
2. Lackner TE, Cloyd JC, Thomas LW, et al. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia. 1998;39:1083-1087.
3. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc. 1998;46:1137-1141.
4. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci. 2000;55:M384-392.
5. Birnbaum AK, Hardie NA, Conway JM, et al. Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res. 2004;62:157-162.
6. Bryson SM, Verma N, Scott PJ, et al. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol. 1983;16:104-105.
7. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665-669.
8. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697-700.
9. Kang D, Verotta D, Schwartz JB. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther. 2006;79:114-124.
10. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology. 2003;60:555-559.
11. Schobben F, van der Kleijn E, Gabreels FJ. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol. 1975;8:97-105.
12. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible mis-interpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32:703-718.
13. Gugler R, Schell A, Eichelbaum M, et al. Disposition of valproic acid in man. Eur J Clin Pharmacol. 1977;12:125-132.
14. McNamara JO. Pharmacotherapy of the epilepsies, in Goodman LS and Gilman A (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Health Professions Division; 1996.
15. Puentes E, Puzantian T, Lum BL. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit. 1999;21:351-354.
16. Bano G, Gupta S, Gupta KL, et al. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. J Assoc Physicians India. 1990;38:629-630.
17. Fattore C, Messina S, Battino D, et al. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res. 2006;70:153-160.
18. Chun AH, Hoffman DJ, Friedmann N, et al. Bioavailability of valproic acid under fasting/nonfasting regimens. J Clin Pharmacol. 1980;20:30-36.
19. Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007;73:275-283.
20. Panesar SK, Orr JM, Farrell K, et al. The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol. 1989;27:323-328.
21. Blanco-Serrano B, Otero MJ, Santos-Buelga D, et al. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos. 1999;20:233-240.
22. Wilson JF, Watson ID, Williams J, et al. Primary standardization of assays for anticonvulsant drugs: comparison of accuracy and precision. Clin Chem. 2002;48:1963-1969.